Hanall Biopharma : Changesof 30% or More in Salesor Profits/Losses(15% or More in the Case of Large-sized Corporations)

Changes of 30% or More in Sales or Profits/Losses (15% or More in the Case of Large-sized Corporations)

※ Note that this disclosure is stated by the concerned company, thus the details may be changed according to audit results. Refer to the disclosure "Submission of Audit Report" for finalized details.
1. Type of financial statements	Consolidated financial statements
2. Details of changes (KRW thou.)	Current fiscal year	Previous fiscal year	Amount increased/ decreased	Increase/ decrease rate (%)
- Sales (limited to amount of revenue according to sales of goods and services provided)	101,594,444	88,602,270	12,992,174	14.7
- Operating income	10,099,119	5,935,188	4,163,931	70.2
- Net income from continuing operation before income tax	8,702,090	19,225,289	-10,523,199	-54.7
- Net income	9,999,967	19,764,499	-9,764,532	-49.4
- Classified as a large-sized corporation?	No
3. Financial status (KRW thou.)	Current fiscal year	Previous fiscal year
- Total assets	199,674,884	220,132,431
- Total liabilities	34,990,576	38,858,948
- Total shareholders' equity	164,684,308	181,273,483
- Capital stock	26,120,319	26,120,319
- Total shareholders' equity/capital stock ratio (%)	630.5	694.0
4. Main causes for changes in sales or profits/losses amount	- The operating income has increased following the influx of milestones through the stable sales growth of major products and clinical development. - The net income for the immediately preceding business year is a temporary effect following the issuance of earnout shares of Immunovant, a global partner
5. Date of board resolution (decision date)	-
- Attendance of outside directors	Present (No.)	-
Absent (No.)	-
- Attendance of auditors (members of Audit Committee who are not outside directors)	-
6. Other matters to be factored into investment decisions
- The above performance results are based on the separate financial statements prepared in accordance with the Korean International Financial Reporting Standards(K-IFRS). - Since the above performance results are the company's provisional settlement figures before the external auditor's review is completed, some of the details may change depending on the results of the external auditor's review.
※ Related disclosure	-

[Matters Related to Parent Company]

Category	Financial statements	Current fiscal year	Previous fiscal year
Total shareholders' equity (excluding non-controlling shareholders' equity)	Consolidated financial statements	164,684,308	181,273,483
Total shareholders' equity/capital stock ratio(%) (excluding non-controlling shareholders' equity)	Consolidated financial statements	630.5	694.0
Sales amount (limited to amount of revenue according to sales of goods and services provided) (KRW thou.)	Non-consolidated financial statements	101,594,444	88,602,270